New potent mexiletine and tocainide analogues evaluated in vivo and in vitro as antimyotonic agents on the myotonic ADR mouse

Neuromuscular Disorders

Volumn 14, Issue 7, 2004, Pages 405-416

  De Luca, Annamaria ^a   Pierno, Sabata ^a   Liantonio, Antonella ^a   Desaphy, Jean François ^a   Natuzzi, Fedele ^a   Didonna, Maria Paola ^a   Ferrannini, Ermanno ^a   Jockusch, Harald ^b   Franchini, Carlo ^a   Lentini, Giovanni ^a   Corbo, Filomena ^a   Tortorella, Vincenzo ^a   Conte Camerino, Diana ^a  

^a UNIVERSITY OF BARI   (Italy)

^b BIELEFELD UNIVERSITY   (Germany)

Author keywords

ADR mouse; Antimyotonic activity; In vitro electrophysiology; In vivo effects; Inherited myotonia; Mexiletine; Newly synthesised analogues; Tocainide

Indexed keywords

1 (2,6 DIMETHYLPHENOXY) 3 METHYL 2 BUTANAMINE; 2 (4 CHLORO 2 METHYLPHENYL)HEXAHYDRO 1H PYRROLO[1,2 C]IMIDAZOL 1 ONE; 3 (2,6 DIMETHYLPHENOXY) 2 METHYLPROPANAMINE; ALPHA [(2,6 DIMETHYLPHENOXY)METHYL]BENZENEMETHANAMINE; ALPHA [(2,6 DIMETHYLPHENOXY)METHYL]BENZENETHANAMINE; AROMATIC COMPOUND; MEXILETINE; N' (2,6 DIMETHYLPHENYL)VALINAMIDE; SODIUM; SODIUM CHANNEL; TOCAINIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DOSE RESPONSE; DRUG ACTIVITY; DRUG EFFECT; DRUG POTENCY; FEMALE; IN VITRO STUDY; IN VIVO STUDY; INTERCOSTAL MUSCLE; MALE; MUSCLE CELL; MYOTONIA; NONHUMAN; PATCH CLAMP; PRIORITY JOURNAL; SKELETAL MUSCLE;

ACTION POTENTIALS; ANALYSIS OF VARIANCE; ANIMALS; ANTI-ARRHYTHMIA AGENTS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTRIC CONDUCTIVITY; ELECTROMYOGRAPHY; FEMALE; INHIBITORY CONCENTRATION 50; MALE; MEXILETINE; MICE; MICE, MUTANT STRAINS; MUSCLE CONTRACTION; MYOTONIC DISORDERS; PATCH-CLAMP TECHNIQUES; SODIUM CHANNELS; STRUCTURE-ACTIVITY RELATIONSHIP; TIME FACTORS; TOCAINIDE;

EID: 2942701895     PISSN: 09608966     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nmd.2004.04.006     Document Type: Article

References (44)

1. Cannon S.C. Ion-channel defects and aberrant excitability in myotonia and periodic paralysis. Trends Neurosci. 19:1996;3-10
2. Jurkat-Rott K., Lerche H., Lehmann-Horn F. Skeletal muscle channelopathies. J Neurol. 249:2002;1493-1502
3. Lehmann-Horn F., Jurkat-Rott K., Rüdel R. Periodic paralysis: understanding channelopathies. Curr Neurol Neurosci Rep. 2:2002;61-69
4. Rüdel R., Lehmann-Horn F., Ricker K. Engel A.G., Franzini-Armstrong C. The non-dystrophic myotonias. 1994;1291-1302 McGraw-Hill, New York
5. Jentsch T.J., Stein V., Weinreich F., Zdebik A.A. Molecular structure and physiological function of chloride channels. Physiol Rev. 82:2002;503-568
6. Ptacek L. The familial periodic paralyses and non-dystrophic myotonias. Am J Med. 104:1998;58-70
7. Labbè L., Turgeon J. Clinical pharmacokinetics of mexiletine. Clin Pharmacokinet. 37:1999;361-384
8. Woosley R.L., Wang T., Stone W., et al. Pharmacology, electrophysiology, and pharmacokinetics of mexiletine. Am Heart J. 107:1984;1058-1065
9. Roden D.M., Woosley R.L. Drug therapy. Tocainide. N Engl J Med. 315:1986;41-45
10. Catterall W.A. Molecular mechanisms of gating and drug block of sodium channels. Novartis Found Symp. 241:2002;206-218
11. Hille B. Local anesthetics: hydrophilic and hydrophobic pathways for the drug-receptor reaction. J Gen Physiol. 69:1977;497-515
12. + channels. Proc Natl Acad Sci USA. 93:1996;9270-9275
13. De Luca A., Natuzzi F., Falcone G., et al. Inhibition of frog skeletal muscle sodium channels by newly synthesized chiral derivatives of mexiletine and tocainide. Naunyn Schmiedebergs Arch Pharmacol. 356:1997;777-787
14. De Luca A., Natuzzi F., Desaphy J.F., et al. Molecular determinants of mexiletine structure for potent and use-dependent block of skeletal muscle sodium channels. Mol Pharmacol. 57:2000;268-277
15. Steinmeyer K., Klocke R., Ortland C., et al. Inactivation of muscle chloride channel by transposon insertion in myotonic mice. Nature. 354:1991;304-308
16. Gronemeier M., Condie A., Prosser J., Steinmeyer K., Jentsch T.J., Jockusch H. Nonsense and missense mutations in the muscular chloride channel gene Clc-1 of myotonic mice. J Biol Chem. 269:1994;5963-5967
17. Mehrke G., Brinkmeier H., Jockusch H. The myotonic mouse mutant ADR: electrophysiology of the muscle fiber. Muscle Nerve. 11:1988;440-446
18. Reininghaus J., Fuchtbauer E.M., Bertram K., Jockusch H. The myotonic mouse mutant ADR: physiological and histochemical properties of muscle. Muscle Nerve. 11:1988;433-439
19. De Luca A., Pierno S., Natuzzi F., et al. Evaluation of the antimyotonic activity of mexiletine and some new analogs on sodium currents of single muscle fibers and on the abnormal excitability of the myotonic ADR mouse. J Pharmacol Exp Ther. 282:1997;93-100
20. + channels enhancing the antimyotonic activity in vivo. Br J Pharmacol. 134:2001;1523-1531
21. Conte Camerino D., Pierno S., De Luca A., Bryant S.H. Antimyotonic effects of tocainide enantiomers on skeletal muscle fibers of congenitally myotonic goats. Neuromuscul Disord. 10:2000;160-164
22. Bryant S.H., Conte-Camerino D. Chloride channel regulation in the skeletal muscle of normal and myotonic goats. Pflügers Arch. 417:1991;605-610
23. Adrian R.H., Bryant S.H. On the repetitive discharge in myotonic muscle fibres. J Physiol (London). 240:1974;505-515
24. Morgan K.G., Bryant S.H. The mechanism of action of dantrolene sodium. J Pharmacol Exp Ther. 201:1977;138-147
25. + channels in a model of myotonia induced by ATX. Br J Pharmacol. 128:1999;1165-1174
26. Franchini C., Cellucci C., Corbo F., et al. Stereospecific synthesis and absolute configuration of mexiletine. Chirality. 6:1994;590-595
27. Carocci A., Franchini C., Lentini G., Loiodice F., Tortorella V. Facile entry to (-)-(R)- and (+)-(S)-mexiletine. Chirality. 12:2000;103-106
28. + channels with increased potency and improved use-dependent activity. J Med Chem. 43:2000;3792-3798
29. Tallarida R.J., Murray R.B. Manual of pharmacological calculations. 1979;Springer, New York
30. Jackson C.E., Barohn R.J., Ptacek L.J. Paramyotonia congenita: abnormal short exercise test, and improvement after mexiletine therapy. Muscle Nerve. 17:1994;763-768
31. Labbe' L., O'Hara G., Lefebvre M., et al. Pharmacokinetic and pharmacodynamic interaction between mexiletine and propafenone in human beings. Clin Pharmacol Ther. 68:2000;44-57
32. Honma W., Kamiyama Y., Yoshinari K., et al. Enzymatic characterization and interspecies difference of phenol sulfotransferases, ST1A forms. Drug Metab Dispos. 29:2001;274-281
33. Longman S.D., Hamilton T.C. Potassium channel activator drugs: mechanism of action, pharmacological properties, and therapeutic potential. Med Res Rev. 12:1992;73-148
34. + channels. Br J Pharmacol. 115:1995;381-382
35. + channel of rat skeletal muscle fibres: a state dependent mechanism of action. Br J Pharmacol. 125:1998;858-864
36. Hoff J. Methods of blood collection in the mouse. Lab Animal. 29:2000;47-53
37. De Luca A., Talon S., De Bellis M., et al. Inhibition of skeletal muscle sodium currents by mexiletine analogues: specific hydrophobic interactions rather than lipophilia per se account for drug therapeutic profile. Naunyn Schmiedebergs Arch Pharmacol. 367:2003;318-327
38. Calabresi P., Cupini L.M., Centonze D., Pisani F., Bernardi G. Antiepileptic drugs as a possible neuroprotective strategy in brain ischemia. Ann Neurol. 53:2003;693-702
39. Grech-Belanger O., Turgeon J., Lalande M., Belanger P.M. Meta-hydroxymexiletine, a new metabolite of mexiletine. Isolation, characterization, and species differences in its formation. Drug Metab Dispos. 19:1991;458-461
40. Turgeon J., Pare J.R., Lalande M., Grech-Belanger O., Belanger P.M. Isolation and structural characterization by spectroscopic methods of two glucuronide metabolites of mexiletine after N-oxidation and deamination. Drug Metab Dispos. 20:1992;762-769
41. Catalano A., Carocci A., Fracchiolla G., et al. Stereospecific synthesis of 'para-Hydroxymexiletine' and sodium channel blocking activity evaluation. Chirality. 16:2004;72-78
42. Desaphy J.F., De Luca A., Tortorella P., De Vito D., George A.L. Jr., Conte Camerino D. Gating of myotonic Na channel mutants defines the response to mexiletine and a potent derivative. Neurology. 57:2001;1849-1857
43. + channel. J Physiol. 537:2001;701-714
44. Weckbecker K., Wurz A., Mohammadi B., et al. Different effects of mexiletine on two mutant sodium channels causing paramyotonia congenita and hyperkalemic periodic paralysis. Neuromuscul Disord. 10:2000;31-39